Skip Nav Destination
            
    
            
 
    
    
        
            
                
                    
                        
                        
                            
                        
                    
                
                    
                    
                        
                    
                
                
                    
                        
                        
                            
                        
                    
            
        
    
    
    
    
        
            
        
        
    
        
    
    
    
 
    
                
                    
            
    
        
    
    
                     
    
                    
        
        
                
            
    
    
    
        
        
     
    
                     
    
                    
        
                    
        
        The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
        
        
            
        
    
        
                
            
    
    
    
        
        
     
    
                    
        
                    
        
        Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
        
        
            
        
    
        
                
            
    
    
    
        
                    
        
        Subclonal TP53 copy number is associated with prognosis in multiple myeloma
        
        
            
        
    
        
                
            
    
    
    
        
        
     
    
                    
        
                    
                
            
    
    
    
        
                    
                
            
    
    
    
        
        
     
    
                    
        
                    
                
            
    
    
    
        
        
     
    
                    
        
                    
                
            
    
    
    
        
        
     
    
                     
    
                     
    
                    
        
        
     
    
 
    
            
    
        
    
         
 
    
    
        
    
            
    
        
    
    
    
        
    
    
    
            
    
                    
 
    
    
 
    
    
        
    
    
    
            
        
 
    
    
 
    
    
        
    
    
    
            
        
            
    
        
        
    
             
            
             
            
             
        
    
 
    
    
 
    
    
        
    
    
    
            
    
                    
 
    
    
 
    
    
 
    
    
    
    
        
    Issue Archive
Table of Contents
BLOOD COMMENTARIES
PLENARY PAPER
PLATELETS AND THROMBOPOIESIS
                    Polyreactive IgM initiates complement activation by PF4/heparin complexes through the classical pathway
            Sanjay Khandelwal,Joann Ravi,Lubica Rauova,Alexandra Johnson,Grace M. Lee,Jennifer B. Gilner,Sreenivasulu Gunti,Abner L. Notkins,Maragatha Kuchibhatla,Michael Frank,Mortimer Poncz,Douglas B. Cines,Gowthami M. Arepally
            
        
    
            BLOOD SPOTLIGHT
CLINICAL TRIALS AND OBSERVATIONS
        
        The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
        
        
            
        
                    
                        Clinical Trials & Observations
                    
        
            
    
        
            Ian W. Flinn,Peter Hillmen,Marco Montillo,Zsolt Nagy,Árpád Illés,Gabriel Etienne,Julio Delgado,Bryone J. Kuss,Constantine S. Tam,Zoltán Gasztonyi,Fritz Offner,Scott Lunin,Francesco Bosch,Matthew S. Davids,Nicole Lamanna,Ulrich Jaeger,Paolo Ghia,Florence Cymbalista,Craig A. Portell,Alan P. Skarbnik,Amanda F. Cashen,David T. Weaver,Virginia M. Kelly,Barry Turnbull,Stephan Stilgenbauer
            
        
    
            LYMPHOID NEOPLASIA
        
        Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
        
        
            
        
                    
                        Clinical Trials & Observations
                    
        
            
    
        
            Aurore Perrot,Valerie Lauwers-Cances,Jill Corre,Nelly Robillard,Cyrille Hulin,Marie-Lorraine Chretien,Thomas Dejoie,Sabrina Maheo,Anne-Marie Stoppa,Brigitte Pegourie,Lionel Karlin,Laurent Garderet,Bertrand Arnulf,Chantal Doyen,Nathalie Meuleman,Bruno Royer,Jean-Richard Eveillard,Lotfi Benboubker,Mamoun Dib,Olivier Decaux,Arnaud Jaccard,Karim Belhadj,Sabine Brechignac,Brigitte Kolb,Cecile Fohrer,Mohamad Mohty,Margaret Macro,Paul G. Richardson,Victoria Carlton,Martin Moorhead,Tom Willis,Malek Faham,Kenneth C. Anderson,Jean-Luc Harousseau,Xavier Leleu,Thierry Facon,Philippe Moreau,Michel Attal,Hervé Avet-Loiseau,Nikhil Munshi
            
        
    
            
        
        Subclonal TP53 copy number is associated with prognosis in multiple myeloma
        
        
            
        
                    
                        Clinical Trials & Observations
                    
                    
                        Brief Report
                    
        
            
    
        
            Vallari Shah,on behalf of the National Cancer Research Institute Haematology Clinical Studies Group,David C. Johnson,on behalf of the National Cancer Research Institute Haematology Clinical Studies Group,Amy L. Sherborne,on behalf of the National Cancer Research Institute Haematology Clinical Studies Group,Sidra Ellis,on behalf of the National Cancer Research Institute Haematology Clinical Studies Group,Frances M. Aldridge,on behalf of the National Cancer Research Institute Haematology Clinical Studies Group,Julie Howard-Reeves,on behalf of the National Cancer Research Institute Haematology Clinical Studies Group,Farzana Begum,on behalf of the National Cancer Research Institute Haematology Clinical Studies Group,Amy Price,on behalf of the National Cancer Research Institute Haematology Clinical Studies Group,Jack Kendall,on behalf of the National Cancer Research Institute Haematology Clinical Studies Group,Laura Chiecchio,on behalf of the National Cancer Research Institute Haematology Clinical Studies Group,Suvi Savola,on behalf of the National Cancer Research Institute Haematology Clinical Studies Group,Matthew W. Jenner,on behalf of the National Cancer Research Institute Haematology Clinical Studies Group,Mark T. Drayson,on behalf of the National Cancer Research Institute Haematology Clinical Studies Group,Roger G. Owen,on behalf of the National Cancer Research Institute Haematology Clinical Studies Group,Walter M. Gregory,on behalf of the National Cancer Research Institute Haematology Clinical Studies Group,Gareth J. Morgan,on behalf of the National Cancer Research Institute Haematology Clinical Studies Group,Faith E. Davies,on behalf of the National Cancer Research Institute Haematology Clinical Studies Group,Richard S. Houlston,on behalf of the National Cancer Research Institute Haematology Clinical Studies Group,Gordon Cook,on behalf of the National Cancer Research Institute Haematology Clinical Studies Group,David A. Cairns,on behalf of the National Cancer Research Institute Haematology Clinical Studies Group,Graham Jackson,on behalf of the National Cancer Research Institute Haematology Clinical Studies Group,Martin F. Kaiser,on behalf of the National Cancer Research Institute Haematology Clinical Studies Group
            
        
    
            MYELOID NEOPLASIA
Bcor insufficiency promotes initiation and progression of myelodysplastic syndrome
            Shiro Tara,Yusuke Isshiki,Yaeko Nakajima-Takagi,Motohiko Oshima,Kazumasa Aoyama,Tomoyuki Tanaka,Daisuke Shinoda,Shuhei Koide,Atsunori Saraya,Satoru Miyagi,Ichiro Manabe,Hirotaka Matsui,Haruhiko Koseki,Vivian J. Bardwell,Atsushi Iwama
            
        
    
            Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia
            Monika Herrmann,Christina Krupka,Katrin Deiser,Bettina Brauchle,Anetta Marcinek,Ana Ogrinc Wagner,Felicitas Rataj,Ralph Mocikat,Klaus H. Metzeler,Karsten Spiekermann,Sebastian Kobold,Nadja C. Fenn,Karl-Peter Hopfner,Marion Subklewe
            
        
    
            PLATELETS AND THROMBOPOIESIS
Platelet-derived TLT-1 is a prognostic indicator in ALI/ARDS and prevents tissue damage in the lungs in a mouse model
            Jessica Morales-Ortíz,Victoria Deal,Fiorella Reyes,Gerónimo Maldonado-Martínez,Nahomy Ledesma,Franklin Staback,Cheyanne Croft,Amanda Pacheco,Humberto Ortiz-Zuazaga,C. Christian Yost,Jesse W. Rowley,Bismark Madera,Alex St. John,Junmei Chen,Jose Lopez,Matthew T. Rondina,Robert Hunter,Angelia Gibson,A. Valance Washington
            
        
    
            TRANSPLANTATION
Indoles derived from intestinal microbiota act via type I interferon signaling to limit graft-versus-host disease
            Alyson Swimm,Cynthia R. Giver,Zachariah DeFilipp,Sravanti Rangaraju,Akshay Sharma,Alina Ulezko Antonova,Robert Sonowal,Christopher Capaldo,Domonica Powell,Muna Qayed,Daniel Kalman,Edmund K. Waller
            
        
    
            LETTER TO BLOOD
BLOOD WORK
ERRATA
- 
        
            Cover Image
        
        
Cover Image
            Hemotoxylin and eosin–stained colon section from a mouse with experimental graft-versus-host disease (GVHD) treated with indole-3-carboxaldehyde (ICA), an indole derivative produced by commensal microbiota. Note that ICA reduces GVHD-associated colitis. See the article by Swimm et al on page 2506.
 - PDF Icon Front MatterFront Matter
 - PDF Icon Table of ContentsTable of Contents
 - PDF Icon Back MatterBack Matter
 - PDF Icon Editorial BoardEditorial Board
 
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals
                    







